Paradigm Spine reported the results of three subanalyses associated with coflex studies.
The data was presented at the International Society for the Advancement of Spine Surgery annual meeting from April 11 to 13 in Toronto. The data highlighted four key findings.
1. Coflex is significantly less invasive than spinal fusion and is associated with shorter operative times, decreased blood loss and shorter hospital lengths of stay.
2. Spinal fusions are $50,000 more expensive than decompression with coflex.
3. For the right patients with lumbar spinal stenosis, coflex can be a less costly alternative to fusion with similar clinical outcomes.
4. Coflex is associated with half the operative time and nearly two days shorter length of stay at the hospital for patients with spinal stenosis grade 1 spondylolisthesis, making it a cost-effective option for the healthcare system.
"Five years after the FDA IDE study, these analyses demonstrate that coflex leads to decreased operative time, less blood loss, shorter hospital stays and overall is significantly less invasive than fusion," said Chairman and CEO of Paradigm Spine Marc Viscogliosi. "As a result, coflex is more cost-effective for the healthcare system while preserving positive clinical outcomes."